Quantcast
Home > Quotes > ARNA
x
ARNA

Arena Pharmaceuticals, Inc. Common Stock (ARNA) Quote & Summary Data

$41.02
*  
1.70
4.32%
Get ARNA Alerts
*Delayed - data as of Oct. 16, 2018 13:31 ET  -  Find a broker to begin trading ARNA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ARNA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 41.01 / $ 41.10
1 Year Target
62.5
Today's High / Low
$ 41.11 / $ 39.1045
Share Volume
184,184
50 Day Avg. Daily Volume
556,430
Previous Close
$ 39.32
52 Week High / Low
$ 50.05 / $ 24.33
Market Cap
2,024,262,713
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.66
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.04

Intraday Chart

News for ARNA

Shares Traded

Share Volume:
184,184
50 Day Avg. Daily Volume:
556,430

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.66

Trading Range

The current last sale of $41.02 is 68.60% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 41.11 $ 50.05
 Low: $ 39.1045 $ 24.33

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver clinical utility across therapeutic areas. Our proprietary, internally-developed pipeline includes multiple potentially first- or best-in-class programs. Our three most advanced investigational clinical programs are: ralinepag (APD811), which we are currently preparing for a Phase 3 program for pulmonary arterial hypertension, or PAH; etrasimod (APD334), which is being studied in Phase 2 trials for immune and inflammatory conditions with an initial focus on ulcerative colitis and hepatic conditions; and APD371 for visceral pain conditions and which is being studied in a Phase 2 trial for treatment of pain associated with Crohn's disease, or CD.  ... More ...  


Risk Grade

Where does ARNA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 39.30
Open Date:
Oct. 16, 2018
Close Price:
$ 39.32
Close Date:
Oct. 15, 2018

Consensus Recommendation

Analyst Info